Treatment of Hepatitis C in 2011: A New Era (By: Hong Gao, MD, Ph.D)

In May of 2011, the FDA approved 2 protease inhibitors (telaprevir and boceprevir) for the treatment of chronic hepatitis C, genotype 1. Telaprevir and boceprevir are used in triple combination with pegylated interferon and ribavirin. The new triple therapy significantly increases the rate of hepatitis C eradication from ~ 50% to up to 80%. The new treatment is indicated for both “naive” patients and patients who failed previous therapy.

Chronic hepatitis C is a complex and potentially progressive liver disease. About 4.1 millions of people in the United States are infected with the hepatitis C virus. Chronic hepatitis C is a leading cause of chronic liver disease and a leading cause of liver transplantation in the U.S. Hepatitis C related mortality has increased substantially since 1995 in the U.S. It is also an important cause of premature deaths in the U.S.

Using a team approach, GI Consultants is currently offering triple therapy to patients with chronic hepatitis C. Our hepatitis C clinic includes a team of physicians, physician assistants and nurses.

Comments are closed.

GI Consultants is accredited by the following: Nevada Colon Cancer Partnership, Screen for Life, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Society of Gastroenterology Nurses and Associates, Inc., Accreditation Association for Ambulatory Health Care, American College of Physicians - Internal Medicine, and is Board Certified by the American College of Gastroenterology.